Additionally, mTOR pathway inhibitors, such as everolimus and vistusertib, have been reported to reduce tumor growth in CCNE1-amplified ovarian xenografts and increase their sensitivity to PARP inhibitors [14]. This evidence concerns the gene CCNE1 and neoplasm.